Q-omics provides the consensus-scored MIR766 profile across patient tissues and cancer cell-line models. MIR766 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MIR766 is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, MIR766 RNA expression shows 8,586 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, and LSCC as cancer lineages where MIR766 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR766 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR766 survival associations across molecular data types. MIR766 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR766 RNA expression–survival associations across cancer types. High MIR766 expression shows unfavorable associations in HNSC, BRCA, LIHC and KIRC, but favorable associations in ESCA and OV. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify HNSC as the clearest survival context for MIR766 RNA expression.
This table summarizes MIR766 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR766. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR766 shows lower tumor expression in ESCA and LUSC and higher tumor expression in HNSC, BLCA and LUAD. The HNSC box plot shows higher MIR766 RNA expression in tumor versus normal tissue (log2 FC = +0.114, t-test p = .002).
This table shows molecular features associated with MIR766 in patient tissues and cancer cell lines. In patient samples, MIR766 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
